Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of “Hold” from Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS) has received an average recommendation of “Hold” from the eleven research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $24.50.

A number of equities research analysts recently commented on the stock. JMP Securities reaffirmed a “market perform” rating on shares of Astria Therapeutics in a report on Wednesday, October 15th. Jefferies Financial Group lowered Astria Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the company from $30.00 to $13.00 in a research note on Tuesday, October 14th. Lifesci Capital cut Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Wedbush set a $13.00 price target on Astria Therapeutics and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Astria Therapeutics in a research note on Wednesday, October 8th.

Astria Therapeutics Stock Performance

NASDAQ ATXS opened at $12.95 on Monday. The company has a market capitalization of $739.19 million, a PE ratio of -6.05 and a beta of 0.07. Astria Therapeutics has a 52-week low of $3.56 and a 52-week high of $13.29. The company has a 50-day simple moving average of $12.64 and a 200 day simple moving average of $8.94.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.14). The business had revenue of $0.71 million for the quarter, compared to analysts’ expectations of $10.67 million. As a group, analysts forecast that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Trading of Astria Therapeutics

A number of institutional investors have recently modified their holdings of the business. Vestal Point Capital LP boosted its holdings in Astria Therapeutics by 9.6% in the 3rd quarter. Vestal Point Capital LP now owns 4,956,000 shares of the biotechnology company’s stock worth $36,080,000 after buying an additional 434,000 shares during the period. Millennium Management LLC lifted its position in shares of Astria Therapeutics by 2.2% during the third quarter. Millennium Management LLC now owns 3,034,527 shares of the biotechnology company’s stock worth $22,091,000 after acquiring an additional 64,800 shares in the last quarter. Brevan Howard Capital Management LP bought a new position in shares of Astria Therapeutics in the third quarter worth $98,000. Raymond James Financial Inc. boosted its holdings in shares of Astria Therapeutics by 6.0% in the third quarter. Raymond James Financial Inc. now owns 96,020 shares of the biotechnology company’s stock worth $699,000 after acquiring an additional 5,437 shares during the period. Finally, Brooklyn Investment Group grew its position in shares of Astria Therapeutics by 204.4% in the third quarter. Brooklyn Investment Group now owns 34,833 shares of the biotechnology company’s stock valued at $254,000 after purchasing an additional 23,389 shares in the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.